These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22672415)

  • 1. MET gain in diffuse astrocytomas is associated with poorer outcome.
    Pierscianek D; Kim YH; Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Wrede K; Nakazato Y; Tanaka Y; Mariani L; Vital A; Sure U; Ohgaki H
    Brain Pathol; 2013 Jan; 23(1):13-8. PubMed ID: 22672415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The definition of primary and secondary glioblastoma.
    Ohgaki H; Kleihues P
    Clin Cancer Res; 2013 Feb; 19(4):764-72. PubMed ID: 23209033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
    Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H
    J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
    Ohgaki H; Kleihues P
    J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic profile of astrocytic and oligodendroglial gliomas.
    Ohgaki H; Kleihues P
    Brain Tumor Pathol; 2011 Jul; 28(3):177-83. PubMed ID: 21442241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
    Watanabe T; Nobusawa S; Kleihues P; Ohgaki H
    Am J Pathol; 2009 Apr; 174(4):1149-53. PubMed ID: 19246647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
    Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDGFRA gain in low-grade diffuse gliomas.
    Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Nonoguchi N; Pierscianek D; Kim YH; Mariani L; Vital A; Perry A; Ohgaki H
    J Neuropathol Exp Neurol; 2013 Jan; 72(1):61-6. PubMed ID: 23242283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copy Number Profiling of Brazilian Astrocytomas.
    Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
    G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival.
    Korkolopoulou P; Levidou G; El-Habr EA; Adamopoulos C; Fragkou P; Boviatsis E; Themistocleous MS; Petraki K; Vrettakos G; Sakalidou M; Samaras V; Zisakis A; Saetta A; Chatziandreou I; Patsouris E; Piperi C
    Br J Cancer; 2013 May; 108(10):2142-52. PubMed ID: 23619925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
    Ichimura K; Pearson DM; Kocialkowski S; Bäcklund LM; Chan R; Jones DT; Collins VP
    Neuro Oncol; 2009 Aug; 11(4):341-7. PubMed ID: 19435942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
    Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
    J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
    Nobusawa S; Watanabe T; Kleihues P; Ohgaki H
    Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas.
    Ohta T; Kim YH; Oh JE; Satomi K; Nonoguchi N; Keyvani K; Pierscianek D; Sure U; Mittelbronn M; Paulus W; Vital A; Yokoo H; McDonald K; Kleihues P; Nazaret N; Barbet F; Lachuer J; Ohgaki H
    J Neuropathol Exp Neurol; 2014 Oct; 73(10):908-15. PubMed ID: 25192052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
    Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
    J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.